Skip to content

A Prospective Clinical Evaluation of the Total Vascular Access (TVA) FLEX-1 Device Protocol Flex-1-002-IR Intervention Reduction (IR)

A Prospective Clinical Evaluation of the TVA FLEX-1 Device Protocol Flex-1-002-IR Intervention Reduction

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02119832
Enrollment
17
Registered
2014-04-22
Start date
2013-04-30
Completion date
2014-02-28
Last updated
2025-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease (CKD)

Keywords

Chronic kidney disease, Arteriovenous fistula, Hemodialysis, Vascular access

Brief summary

The primary objective of this clinical study is to evaluate the preliminary safety and effectiveness of using the FLEX-1 device for the creation of an arteriovenous fistula (AVF) including coiling of the brachial vein during the index procedure in patients requiring chronic hemodialysis.

Interventions

DEVICEEndovasccular AVF (EndoAVF)

The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access

Sponsors

C. R. Bard
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Eligible for a native surgical arteriovenous fistula, as determined by the treating physician. * Adult (age \>18 years old). * Advanced chronic kidney disease (CKD), stage 4 or 5 electing for hemodialysis. * Written informed consent obtained

Design outcomes

Primary

MeasureTime frameDescription
Adverse Events6 monthsThe safety of the FLEX-1 system based on the overall complication rates derived from adverse event data.

Secondary

MeasureTime frameDescription
Access Functionality6 monthsThe functionality of the AVF will be measured based on use of the AVF with two needles for at least 75% of dialysis sessions over a 4-week period following at least a one month maturation period.

Countries

Paraguay

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026